Company: PFSA
Filing Date: 2025-05-09
Form Type: S-4/A
Source: 0001213900-25-041151
Chunk: 188

Company: Profusa, Inc.
Filing Date: 2025-05-09
Form: S-4/A
Chunk 188
---
 results may be significantly higher or lower than projected in the forecasts. The forecasts also reflect assumptions as to certain business strategies or plans that are subject to change. As a result, the inclusion of such forecasts in this proxy statement/prospectus should not be relied on as “guidance” or otherwise predictive of actual future events, and actual results may differ materially from the forecasts. NorthView and Profusa have incurred and expect to incur significant costs associated with the Business Combination. Whether or not the Business Combination is completed, the incurrence of these costs will reduce the amount of cash available to be used for other corporate purposes by NorthView if the Business Combination is not completed. Each of NorthView and Profusa has incurred and expects that it will incur significant, non -recurringcosts in connection with the Business Combination and operating as a public company following the Closing. NorthView and Profusa may also incur additional costs to retain key employees. NorthView and Profusa will also incur significant legal, financial advisor, accounting, banking and consulting fees, fees relating to regulatory filings and notices, SEC filing fees, printing and mailing fees and other costs associated with the Business Combination, which will be paid by New Profusa following the Closing. Even if the Business Combination is not completed, NorthView expects to incur approximately $2.0 million in expenses. These expenses will reduce the amount of cash available to be used for other corporate purposes by NorthView if the Business Combination is not completed. Warrants will become exercisable for New Profusa Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders. Outstanding warrants to purchase an aggregate of 17,404,250shares of New Profusa Common Stock will become exercisable in accordance with the terms of the Warrant Agreement governing those securities. The exercise price of these warrants will be $11.50 per share. To the extent such warrants are exercised, additional shares of New Profusa Common 83 Stock will be issued, which will result in dilution to the holders of New Profusa Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the market price of New Profusa Common Stock. However, there is no guarantee that the public warrants will ever be in the money prior to their expiration, and as such, the warrants may expire worthless. See “— Even if NorthView consummates the